Adaptive Multiple Testing Procedure for Clinical Trials with Urn Allocation

Author:

Hammouri Hanan1ORCID,Ali Mohammed1ORCID,Alquran Marwan1,Alquran Areen2,Abdel Muhsen Ruwa3,Alomari Belal1

Affiliation:

1. Department of Mathematics and Statistics, Faculty of Science and Art, Jordan University of Science and Technology, P.O. Box 3030, Irbid 22110, Jordan

2. Department of Statistics, Yarmouk University, Irbid 21163, Jordan

3. Department of Mathematical Sciences, New Mexico State University, Las Cruces, NM 88001, USA

Abstract

This work combines the Urn allocation and O’Brien and Fleming multiple testing procedure to compare two treatments in clinical trials in a novel way. It is shown that this approach overcomes the constraints that previously made it challenging to apply the original adaptive design to clinical trials. The method provides unique flexibility, enabling trials to be stopped early if one treatment shows it is superior without compromising the efficiency of the original multiple testing procedure in terms of type I error rate and power. Experimental data and simulated case examples are used to illustrate the efficacy and robustness of this original approach and its potential for usage in a variety of clinical settings.

Funder

Deanship of Scientific Research at Jordan University of Science and Technology

Publisher

MDPI AG

Subject

General Mathematics,Engineering (miscellaneous),Computer Science (miscellaneous)

Reference45 articles.

1. FDA introductory comments: Clinical studies design and evaluation issues;Woodcock;Clin. Trials,2005

2. US Department of Health and Human Services (2017, January 01). Draft Guidance. Multiple Endpoints in Clinical Trials Guidance for Industry. Center for Biologics Evaluation and Research (CBER). Available online: https://pink.citeline.com/-/media/supporting-documents/pink-sheet/2017/01/fda-draft-guidance-multiple-endpoints-in-clinical-trials-01-12-2017.pdf.

3. EMA (2022, June 01). Guideline on Multiplicity Issues in Clinical Trials. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-multiplicity-issues-clinical-trials_en.pdf.

4. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review;Hamasaki;J. Biopharm. Stat.,2018

5. US Department of Health and Human Services (2018, October 01). Guidance for Industry. Adaptive Designs for Clinical Trials of Drugs and Biologics. Center for Biologics Evaluation and Research (CBER). Available online: https://www.researchgate.net/profile/Sitansu-Nanda/publication/332971221_Adaptive_Designs_for_Clinical_Trials_of_Drugs_and_Biologics_Guidance_for_Industry_DRAFT_GUIDANCE/links/5cd43e83299bf14d95849a80/Adaptive-Designs-for-Clinical-Trials-of-Drugs-and-Biologics-Guidance-for-Industry-DRAFT-GUIDANCE.pdf.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3